Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of osimertinib plus
ramucirumab versus osimertinib alone using progression free survival (PFS). Events associated
with PFS include: disease progression per RECIST 1.1 and death due to any cause. A total of
150 patients will be enrolled and randomized in a 2:1 fashion (osimertinib plus ramucirumab
vs. osimertinib) to the two treatment arms according to the following stratification factors:
types of epidermal growth factor receptor (EGFR) mutations and presence of brain metastasis.